Assessment of MUM1 Expression, Lymphoma-Associated Macrophages, and Regulatory T-Cells in Follicular Lymphoma: Prognostic Markers in SWOG S8809 and S9800/S9911 Trials Representing Pre-and Post-Monoclonal Antibody Therapy Protocols
- Determine the prognostic significance of MUM-1, lymphoma-associated macrophages, and
regulatory T cells in patients with follicular lymphoma treated on clinical trials
SWOG-8809, SWOG-9800, or SWOG-9911 representing pre- and post-monoclonal antibody
- Determine whether these factors have similar prognostic significance in patients
treated with chemotherapy alone vs chemotherapy and monoclonal antibody therapy on
these clinical trials.
OUTLINE: This is a multicenter study.
Previously collected tissue samples from patients are analyzed by immunohistochemistry, gene
expression profiling, and quantitative analysis for MUM1 expression, lymphoma-associated
macrophages, FOXP3-positive regulatory T cells, CD68, and CD163.
PROJECTED ACCRUAL: A total of 318 samples will be accrued for this study.
Prognostic significance of MUM-1, lymphoma-associated macrophages, and regulatory T cells
John W. Sweetenham, MD
The Cleveland Clinic